South Korea Biosimilars Market Size & Outlook, 2026-2033
Global Market
Related Markets
South Korea biosimilars market highlights
- The South Korea biosimilars market generated a revenue of USD 689.1 thousand in 2025 and is expected to reach USD 2,958.4 thousand by 2033.
- The South Korea market is expected to grow at a CAGR of 20.1% from 2026 to 2033.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating drug class in 2025.
- Insulin & Analogues is the most lucrative drug class segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2025 | USD 689.1 thousand |
| Market revenue in 2033 | USD 2,958.4 thousand |
| Growth rate | 20.1% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Insulin & Analogues |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD thousand |
| Market segmentation | Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents, Insulin & Analogues, Osteoporosis / Bone Metabolism Agents, Others Drug Class |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.7% of the global biosimilars market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China biosimilars market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,947.2 thousand by 2033.
The South Korean government has invested heavily in domestic biopharmaceutical companies by providing capital and regulatory assistance. For instance, in 2011, the government reportedly began a consulting program in order to help South Korean biopharmaceutical companies understand the regulatory process for biosimilar approval at home and abroad.
And in 2012, the government invested over 35% of the national medical R&D budget in biosimilars development. South Korea’s early investments in the biosimilars industry are helping two companies in the country namely, Celltrion and Samsung Bioepis, both have received approval for biosimilars of blockbuster drugs.
Celltrion’s infliximab biosimilar is currently approved in various countries and is aiming for USD 1 billion in global sales of the drug. The company stated that they intend to invest an additional USD 275 million at their Korean manufacturing site in order to gain more production capacity by 2021.
No credit card required*
Publish Date: Nov 05, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.drreddys.com/ |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbioepis.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
South Korea Biosimilars Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimilars Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies (Mabs) was the largest segment with a revenue share of 53.24% in 2025.
Horizon Databook has segmented the South Korea biosimilars market based on monoclonal antibodies (mabs), growth factors & hematopoietic agents, insulin & analogues, osteoporosis / bone metabolism agents, others drug class covering the revenue growth of each sub-segment from 2021 to 2033.
The South Korean government has invested heavily in domestic biopharmaceutical companies by providing capital and regulatory assistance. For instance, in 2011, the government reportedly began a consulting program in order to help South Korean biopharmaceutical companies understand the regulatory process for biosimilar approval at home and abroad.
And in 2012, the government invested over 35% of the national medical R&D budget in biosimilars development. South Korea’s early investments in the biosimilars industry are helping two companies in the country namely, Celltrion and Samsung Bioepis, both have received approval for biosimilars of blockbuster drugs.
Celltrion’s infliximab biosimilar is currently approved in various countries and is aiming for USD 1 billion in global sales of the drug. The company stated that they intend to invest an additional USD 275 million at their Korean manufacturing site in order to gain more production capacity by 2021.
- South Korea Biosimilars Market Drug Class Outlook (Revenue, USD Thousand , 2021-2033)
- Monoclonal Antibodies (mAbs)
- Growth Factors & Hematopoietic Agents
- Insulin & Analogues
- Osteoporosis / Bone Metabolism Agents
- Others
- South Korea Biosimilars Market Indication Outlook (Revenue, USD Thousand , 2021-2033)
- Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
- Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
- Diabetes Mellitus (Type 1 & Type 2)
- Ophthalmic Disorders (Wet AMD, DME, RVO)
- Hematologic / Rare Blood Disorders
- Others
- South Korea Biosimilars Market End Use Outlook (Revenue, USD Thousand , 2021-2033)
- Hospitals
- Specialty Pharmacies
- Online & Retail Channels
Reasons to subscribe to Biosimilars Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimilars Market Outlook databook
- Our clientele includes a mix of Biosimilars Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Biosimilars Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Biosimilars Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
South Korea Biosimilars Market, 2021-2033 (US$K)
South Korea biosimilars market statistics, by drug class, 2021-2033 (USD Thousand)
